GlassScriptPhysician profile
Daniel Livingston
NPI 1902105687
$2,747.69
in general payments reported to CMS, 2019-2025
27 companies · $1,149 in 2025
The $1,149 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.81 · 2022: $128 · 2023: $737 · 2024: $716 · 2025: $1,149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,602.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,602.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $856.74 | 2022-2025 | Breztri, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $457.51 | 2023-2025 | Nucala, Trelegy Ellipta |
| Baxter Healthcare | $125.00 | 2023-2025 | Hillrom - Monarch Airway Clearance System, Hillrom - Vest System Model 105 Home Care |
| Regeneron Healthcare Solutions, INC. | $119.97 | 2023-2025 | Dupixent |
| Amgen INC. | $106.02 | 2023-2025 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.20 | 2022-2025 | Spiriva Respimat, Ofev, Stiolto Respimat |
| Actelion Pharmaceuticals US, INC. | $91.99 | 2022-2025 | Opsumit, Uptravi |
| Takeda Pharmaceuticals U.S.A., INC. | $91.19 | 2023-2025 | Glassia |
| Grifols USA, LLC | $87.46 | 2023-2024 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $81.75 | 2022-2024 | Yupelri |
| Mallinckrodt Hospital Products INC. | $77.39 | 2024-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $71.86 | 2023-2025 | |
| Viatris Specialty LLC | $59.80 | 2025 | Yupelri |
| Abbvie INC. | $53.34 | 2025 | |
| Merck Sharp & Dohme LLC | $48.92 | 2023-2024 | Dificid, Zerbaxa, Recarbrio |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $46.34 | 2022-2024 | |
| Insmed, INC. | $37.53 | 2024-2025 | Arikayce |
| Pfizer INC. | $32.73 | 2023-2025 | |
| United Therapeutics Corporation | $31.56 | 2025 | Tyvaso |
| Pulmonx Corporation | $30.19 | 2023-2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Philips North America LLC | $26.92 | 2023-2024 | (Ak6) Vest Therapy |
| Genentech USA, INC. | $22.51 | 2024 | Tecentriq |
| Hologic Sales and Service, LLC | $19.70 | 2022 | |
| Tactile Systems Technology INC | $18.71 | 2023 | Entre Plus, Flexitouch Plus |
| Vapotherm INC | $17.81 | 2021 | |
| Electromed, INC. | $15.33 | 2025 | Smartvest |
| Verona Pharma, INC. | $14.22 | 2025 | Ohtuvayre |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Livingston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.